Four Novel Metabolite-Driven PTMs Are Redrawing the Post-Translational Modification Landscape

When Metabolites Become Writers of the Proteome

Proteins rarely act as unmodified entities. Post-translational modifications (PTMs) are dynamic, reversible chemical changes that tune protein activity, localization, interactions and stability without altering the amino acid sequence. Since phosphorylation was first described in 1906, classic modifications such as acetylation and ubiquitination have established the enzymatic framework of "Writer – Eraser – Reader", in which dedicated enzymes install, remove and interpret each chemical mark.

A decisive shift came in 2019, when the discovery of histone lactylation brought a glycolytic end product into the PTM chemical space. Over the following years, succinylation, crotonylation and other acyl-lysine marks were systematically characterized, and metabolite-driven PTM evolved from isolated observations into a modification class with defined enzymatic regulation. In 2026, this field entered a remarkably productive phase: within half a year, four new metabolite-driven modifications — pyruvylation, fumarylation, D/L-2-hydroxyglutarate (2HG) modifications and phenylacetylation — were reported back to back in leading journals including Cell, Nature Metabolism, JACS, Nature Chemistry and Cell Metabolism.

Figure 1. Key milestones in PTM research, from the discovery of phosphorylation to the metabolite-driven modification era. (Adapted from Signal Transduct Target Ther. 2026 Aug 7;11(1):314.)

Lysine Pyruvylation (Kpy): Glycolytic Flux Written onto Immunity and Chromatin

Two landmark studies in 2026 established lysine pyruvylation, a modification in which pyruvate — the final product of glycolysis — is covalently attached to lysine residues, acting as a molecular switch that connects metabolic state to epigenetics and innate immunity.

In April, the team of Zheng Hui at the University of Electronic Science and Technology of China reported in Cell that pyruvate covalently modifies STAT1 at lysine 201 (K201), a residue located at the STAT1–STAT2 interaction interface. Pyruvylation at this site creates steric hindrance that blocks heterodimer assembly, thereby suppressing type I interferon (IFN-I) signaling and reducing the expression of interferon-stimulated genes. Quantitative analysis showed that when glucose concentration rises and glycolysis is activated, the occupancy of STAT1-K201 pyruvylation increases from approximately 1% to 30% — metabolic state directly determines the modification level and functional output of an immune protein. A STAT1-K201R knock-in mouse model confirmed the physiological relevance: under viral challenge, the knock-in animals mounted a normal IFN-I response, recovered antiviral gene expression and showed significantly improved survival. Analysis of human clinical samples echoed these findings, as hyperglycemic individuals showed elevated STAT1 pyruvylation together with impaired interferon responses.

Figure 2. Chemical structure of lysine pyruvylation: a pyruvoyl group is attached to the ε-amino group of a lysine residue.

Figure 3. Graphical abstract of the Cell study reporting pyruvate as a natural suppressor of interferon signaling through STAT1 pyruvylation. (Cell. 2026 Apr 2;189(7):1975-1989.e19.)

Figure 4. Nature Metabolism study: "Lysine pyruvylation couples glycolytic flux to epigenetic regulation". (Nat Metab. 2026 Jul;8(7):1495-1507.)

In July, the team of Huang He at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, delivered a systematic characterization of lysine pyruvylation in Nature Metabolism. Using modification proteomics, the researchers identified 10 histone Kpy sites and 78 non-histone Kpy sites in mammalian cells, and detected Kpy signals in E. coli, yeast and mammalian cells, indicating strong evolutionary conservation. The study also defined the enzymatic network: HAT1 and p300 (EP300) act as Writers catalyzing lysine pyruvylation using pyruvoyl-CoA as the substrate, while SIRT3 functions as the Eraser that removes the mark. Using CUT&Tag, the team mapped the genomic binding landscape of Kpy and found strong enrichment at gene promoters; combined with transcriptomics, histone pyruvylation was shown to drive transcriptional activation of targets including FGFR4 and LGALS8, feeding glycolytic signals directly into the nuclear epigenetic network.

Figure 5. The regulatory landscape of lysine pyruvylation: HAT1 and p300 as Writers, SIRT3 as Eraser, linking glycolytic flux to cytosolic IFN-I signaling and nuclear chromatin regulation.

Together, these studies outline a complete regulatory logic: cytosolic pyruvylation suppresses STAT1-mediated interferon signaling, while nuclear pyruvylation reshapes chromatin transcriptional states. This "metabolism – immunity – epigenetics" triad positions pyruvylation as a central node connecting the Warburg effect with cell fate decisions.

Lysine Fumarylation (Kfu): The Last Word of the TCA Cycle

In April 2026, the teams of Zhang Kai and Chen Chen at Tianjin Medical University reported in JACS the first systematic characterization of lysine fumarylation. Using open-search mass spectrometry in E. coli, the researchers detected a mass shift of +98.0002 Da on lysine residues, corresponding to an amide bond formed between fumaric acid and lysine — chemically distinct from the previously known cysteine succination/fumarate Michael addition.

Figure 6. Chemical structure of fumaryl-lysine, formed through an amide linkage between fumaric acid and the lysine ε-amino group.

Figure 7. JACS study: discovery and enzymatic regulation of lysine fumarylation, a post-translational modification in bacteria. (J Am Chem Soc. 2026 Apr 22;148(15):16502-16514.)

Fumarylation carries an independent enzymatic regulatory system: the SucC/D complex converts fumarate into fumaryl-CoA, and SpeG transfers the fumaryl group onto substrate lysine residues, while CobB, an NAD⁺-dependent deacylase, serves as the Eraser. In total, 857 endogenous fumarylation sites were identified. Integrated transcriptomic and proteomic analyses showed that these sites are highly concentrated in stress-response proteins, including temperature-shock proteins, oxidoreductases and metabolic regulators. When cells encounter hypoxia, heat or oxidative stress, the TCA cycle is obstructed and fumarate accumulates, making fumarylation a stress-responsive modification that rapidly reprograms protein function networks.

An important caveat remains: the modification has so far been fully validated in bacterial systems, and the existence and function of endogenous lysine fumarylation in mammalian cells await confirmation. Even so, the discovery completes a picture in which every intermediate of the TCA cycle — succinyl, malonyl and now fumaryl — has its own protein "language".

Figure 8. The molecular pathway of lysine fumarylation: SucC/D generates fumaryl-CoA, SpeG transfers the fumaryl group onto lysine, and CobB removes the mark.

D/L-2HG Modifications: Chirality Selects the Targets

2-hydroxyglutarate (2HG) is the hallmark oncometabolite of IDH1/2-mutant tumors. Cells actually produce two chiral isomers: D-2HG, generated by mutant IDH1/2, and L-2HG, produced under hypoxia through aberrant catalysis by lactate dehydrogenase or malate dehydrogenase. Conventional wisdom treated them as one molecule in two forms, differing only in abundance.

In Nature Chemistry, the team of W. Andy Tao at Purdue University showed that chirality fundamentally changes the target spectrum. Using chemical proteomics in IDH1-mutant cholangiocarcinoma cells, the researchers systematically mapped covalent 2HG modifications on proteins. O-linked ester modifications on serine, threonine and tyrosine residues dominate, alongside N-linked amide bonds on lysine and S-linked thioesters on cysteine. Most target proteins modified by each isomer are distinct: D2HG-modified proteins are enriched in ATP binding and chromatin remodeling, whereas L2HG-modified proteins are associated with RNA binding and oxidative stress response. Functionally, 2HG modification directly suppresses kinase activity: D2HG modification of MRCKA at S794 reduces phosphorylation of its substrate PPP1R12A, and L2HG modification of SLK at S719 reduces PLK1 T210 phosphorylation, with potential consequences for mitotic regulation.

Figure 9. Chirality-dependent protein modification by D-2HG and L-2HG: the two isomers modify largely distinct target proteins.

Figure 10. Nature Chemistry study: discovery of chirally dependent protein modifications by D- and L-2-hydroxyglutarates. (Nat Chem. 2026 Jun;18(6):1033-1041.)

These findings recast D2HG and L2HG not as two concentrations of one molecule, but as two signaling systems with distinct target profiles and functional outputs — opening a route toward therapeutic targets in IDH-mutant tumors and hypoxia-related diseases.

Lysine Phenylacetylation (Kpaa): When the Microbiome Writes on Host Proteins

In June 2026, the teams of Tan Minjia, Li Jingya and Xu Junyu at the Shanghai Institute of Materia Medica, together with Ye Bangce at East China University of Science and Technology, reported in Cell Metabolism the discovery of lysine phenylacetylation — the first lysine acylation shown to be directly driven by a gut microbial metabolite, establishing a complete evidence chain from gut bacteria to host protein modification to disease.

Mechanistically, dietary phenylalanine is metabolized by specific gut bacteria into phenylacetic acid (PAA). After entering host cells, the acyl-CoA synthetase ACSF2 converts PAA into phenylacetyl-CoA, the active acyl donor that modifies protein lysine residues; the mitochondrial deacylase SIRT3 removes the mark, making the modification reversible. Whole-proteome analysis showed that Kpaa substrates are highly enriched in mitochondrial proteins, with the molecular chaperone HSP60 at K481 as a key functional site: phenylacetylation of HSP60 K481 triggers the mitochondrial unfolded protein response, causing mitochondrial proteostasis imbalance, reduced oxidative phosphorylation efficiency and massive reactive oxygen species accumulation.

Figure 11. The gut microbiota–derived phenylacetylation axis: dietary phenylalanine is converted by gut bacteria into phenylacetic acid, activated by ACSF2 into phenylacetyl-CoA, installed on lysine residues and removed by SIRT3.

Figure 12. Cell Metabolism study: gut microbiota-derived lysine phenylacetylation in metabolic dysfunction-associated steatotic liver disease. (Cell Metab. 2026.)

On the disease side, the study focused on MASLD/MASH (metabolic dysfunction-associated steatotic liver disease / steatohepatitis). A high-fat diet reshapes gut microbiota composition and expands PAA-producing bacteria, raising hepatic Kpaa levels. Clinical samples confirmed that liver Kpaa levels in obese patients correlate positively with MASH pathology progression and negatively with SIRT3 expression — a complete microbiota–host modification axis running from diet to fatty liver disease.

Four New Modifications at a Glance

The four modifications described in 2026 expand the chemical space of metabolite-driven PTMs from four distinct directions: glycolysis, the TCA cycle, oncometabolite chemistry and the gut microbiota.

A Maturing Research Paradigm for New PTMs

Looking back at how these four modifications moved from an anomalous mass shift on a mass spectrum to biologically validated events with defined chemistry, enzymatic regulation and pathological relevance, a reproducible workflow has emerged. For researchers planning to enter a new modification field, this path offers a practical template:

1. Detect the anomaly. Use open-search mass spectrometry or chemical proteomics to identify unexpected mass shifts and lock in candidate modifications. For low-abundance marks, peptide fractionation (high-pH reversed phase, strong cation exchange) improves sensitivity, and chemically synthesized standards confirm structures by retention time and fragmentation patterns.
2. Identify the enzymes. Screen for Writers and Erasers through knockout or overexpression of candidate enzymes, combined with in vitro assays using recombinant proteins, to demonstrate enzymatic control rather than random chemical accumulation.
3. Map the sites. Enrich modified peptides with modification-specific antibodies or chemical probes, quantify sites by high-resolution mass spectrometry and analyze subcellular localization and pathway enrichment of the substrates.
4. Prove the function. Introduce site-specific mutations (for example K→R), map protein interactions by Co-IP or SPR and apply molecular dynamics simulations to clarify how the modification changes target activity, localization or complex assembly.

How ANTBIO Supports Metabolite-Driven PTM Research

Studying a newly reported modification demands reagents that recognize the chemical mark with high specificity, plus tools for the enzymes and substrates that frame its biology. ANTBIO offers a growing portfolio of pan-lysine acylation antibodies, enzyme antibodies and 2HG-related reagents that map directly onto the four modifications summarized above. The same toolkit extends across the group: Starter supplies acylation antibodies and the agarose beads used for enrichment, and Absin provides the metabolite reagents (sodium pyruvate, D-(+)-glucose) that feed these pathways.

Pan-lysine acylation antibody panel

The S-RMabMix™ series covers the established acyl-lysine landscape and now extends to the two newest additions reported in 2026, including dedicated antibodies for pyruvyl-lysine and fumaryl-lysine.

Enzymes, substrates and supporting reagents

Beyond the marks themselves, the enzymes that install and remove them, and the substrate proteins through which they act, are equally central to experimental design.

Build Your PTM Toolkit

Whether you are setting up open-search discovery, building enrichment workflows with modification-specific antibodies, or validating a newly reported mark in your own system, our team can help you select the right antibodies and reagents for each step. For product details, datasheets or a quotation, please contact us at info@antbioinc.com.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.